Edesa Biotech (EDSA) Stock Forecast, Price & News

Edesa Biotech (NASDAQ:EDSA) Frequently Asked Questions

Is Edesa Biotech a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edesa Biotech in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Edesa Biotech stock.
View analyst ratings for Edesa Biotech or view top-rated stocks.

When is Edesa Biotech's next earnings date?

Edesa Biotech is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Edesa Biotech.

How were Edesa Biotech's earnings last quarter?

Edesa Biotech, Inc. (NASDAQ:EDSA) announced its earnings results on Friday, May, 13th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.04.
View Edesa Biotech's earnings history.

What price target have analysts set for EDSA?

1 equities research analysts have issued 1-year price objectives for Edesa Biotech's shares. Their forecasts range from $16.00 to $16.00. On average, they expect Edesa Biotech's share price to reach $16.00 in the next year. This suggests a possible upside of 784.0% from the stock's current price.
View analysts' price targets for Edesa Biotech or view top-rated stocks among Wall Street analysts.

Who are Edesa Biotech's key executives?

Edesa Biotech's management team includes the following people:

• Dr. Pardeep Nijhawan FRCPC, M.D., CEO, Company Sec. & Director (Age 51, Pay $498.77k)
• Dr. Michael J. Brooks M.B.A., Ph.D., Pres (Age 44, Pay $446.09k)
• Ms. Kathi Niffenegger CPA, CPA, Chief Financial Officer (Age 65, Pay $435.92k)
• Mr. Gary Koppenjan, VP of Investor Relations & Communications
• Mr. Rajan Puri, Sr. VP of Manufacturing

Who are some of Edesa Biotech's key competitors?

Some companies that are related to Edesa Biotech include Endo International (ENDP), Alaunos Therapeutics (TCRT), Werewolf Therapeutics (HOWL), UroGen Pharma (URGN), Selecta Biosciences (SELB), Leap Therapeutics (LPTX), NervGen Pharma (NGENF), Entasis Therapeutics (ETTX), Anixa Biosciences (ANIX), Sesen Bio (SESN), Greenwich LifeSciences (GLSI), Xynomic Pharmaceuticals (XYNO), CytomX Therapeutics (CTMX), Satsuma Pharmaceuticals (STSA) and NextCure (NXTC).
View all of EDSA's competitors.

What other stocks do shareholders of Edesa Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edesa Biotech investors own include Pfizer (PFE), AbbVie (ABBV), VBI Vaccines (VBIV), Vaxart (VXRT), Exxon Mobil (XOM), Anavex Life Sciences (AVXL), Occidental Petroleum (OXY), Sorrento Therapeutics (SRNE), AT&T (T) and Amarin (AMRN).

What is Edesa Biotech's stock symbol?

Edesa Biotech trades on the NASDAQ under the ticker symbol "EDSA."

Who are Edesa Biotech's major shareholders?

Edesa Biotech's stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.59%) and National Bank of Canada FI (0.07%). Company insiders that own Edesa Biotech stock include Frank R Oakes, Michael J Brooks and Pardeep Nijhawan.
View institutional ownership trends for Edesa Biotech.

Which institutional investors are buying Edesa Biotech stock?

EDSA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and National Bank of Canada FI. Company insiders that have bought Edesa Biotech stock in the last two years include Michael J Brooks, and Pardeep Nijhawan.
View insider buying and selling activity for Edesa Biotech or or view top insider-buying stocks.

How do I buy shares of Edesa Biotech?

Shares of EDSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Edesa Biotech's stock price today?

One share of EDSA stock can currently be purchased for approximately $1.81.

How much money does Edesa Biotech make?

Edesa Biotech has a market capitalization of $27.99 million and generates $330 thousand in revenue each year. The company earns $-13.34 million in net income (profit) each year or ($1.290010) on an earnings per share basis.

How many employees does Edesa Biotech have?

Edesa Biotech employs 16 workers across the globe.

What is Edesa Biotech's official website?

The official website for Edesa Biotech is www.edesabiotech.com.

How can I contact Edesa Biotech?

Edesa Biotech's mailing address is 100 SPY COURT, MARKHAM A6, L3R 5H6. The company can be reached via phone at (289) 800-9600, via email at investors[email protected], or via fax at 805-488-2889.